Fresenius Medical Care AG

FMS

Equity

ISIN US3580291066 / Valor 523134

New York Stock Exchange, Inc (2024-09-16)

USD 20.93-0.76%

Fresenius Medical Care AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Fresenius Medical Care AG is a global healthcare company specializing in products and services for individuals with renal diseases, including those requiring dialysis treatment. As the world's leading provider in this sector, the company offers a comprehensive range of dialysis services and products, such as dialysis machines and dialyzers, catering to approximately 4.1 million patients globally who regularly undergo dialysis. Beyond its primary focus on the Renal Care Continuum, Fresenius Medical Care is also expanding its expertise into complementary areas and critical care. This strategic diversification underscores the company's commitment to addressing the complex needs of patients with renal diseases and related conditions, leveraging its extensive experience and innovation in healthcare solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2024, Fresenius Medical Care AG reported revenue of EUR 4,725 million, reflecting a 2% increase at constant currency and a 5% organic growth. The revenue growth was driven by both the Care Delivery and Care Enablement segments, with Care Delivery U.S. showing a notable increase due to a growing value-based care business and favorable reimbursement rates.

Operating Income

Fresenius Medical Care AG's operating income for Q1 2024 decreased by 6% to EUR 246 million, resulting in a margin of 5.2%. However, when adjusted for constant currency, special items, and the impacts of closed divestitures, the operating income increased by 23% to EUR 416 million, with a margin of 8.6%. This improvement was driven by positive pricing effects and savings from the FME25 program.

Net Income

Net income for Fresenius Medical Care AG in the first quarter of 2024 decreased by 18% to EUR 71 million. On an outlook base, which excludes special items and divestiture impacts, net income increased by 35%. Basic earnings per share (EPS) also saw a decrease of 18% to EUR 0.24, but on an outlook base, EPS increased by 35%.

Cash Flow

Fresenius Medical Care AG generated EUR 127 million in operating cash flow during Q1 2024, resulting in a margin of 2.7%. The operating cash flow was negatively impacted by EUR 58 million due to a cyber incident at Change Healthcare, a U.S. service provider. Free cash flow for the quarter amounted to EUR -2 million.

Outlook for 2024

Fresenius Medical Care AG confirmed its financial outlook for fiscal 2024, expecting revenue to grow by a low- to mid-single digit percent rate compared to the prior year. The company also anticipates operating income to grow by a mid- to high-teens percent rate. The targets include achieving an operating income margin of 10% to 14% by 2025, excluding impacts from portfolio changes.

Summarized from source with an LLMView Source

Key figures

-6.56%1Y

-40.8%3Y

-39.8%5Y

Performance

37.5%1Y

34.7%3Y

32.2%5Y

Volatility